These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2484083)

  • 1. Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme.
    DeForrest JM; Waldron TL; Krapcho J; Turk C; Rubin B; Powell JR; Cushman DW; Petrillo EW
    J Cardiovasc Pharmacol; 1989 Jun; 13(6):887-94. PubMed ID: 2484083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology.
    DeForrest JM; Waldron TL; Harvey C; Scalese B; Rubin B; Powell JR; Petrillo EW; Cushman DW
    J Cardiovasc Pharmacol; 1989 Nov; 14(5):730-6. PubMed ID: 2481187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sites of first-pass bioactivation (hydrolysis) of orally administered zofenopril calcium in dogs.
    Morrison RA; Burkett DE; Arnold ME; D'Arienzo CJ; Weinstein SH
    Pharm Res; 1991 Mar; 8(3):370-5. PubMed ID: 2052527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceranapril (SQ 29,852), an orally active inhibitor of angiotensin converting enzyme (ACE).
    DeForrest JM; Waldron TL; Harvey C; Scalese R; Hammerstone S; Powell JR; Karanewsky D
    J Cardiovasc Pharmacol; 1990 Jul; 16(1):121-7. PubMed ID: 1696654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
    Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
    Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals?
    Westlin W; Mullane K
    Circulation; 1988 Jun; 77(6 Pt 2):I30-9. PubMed ID: 2836109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
    Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
    J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.
    Grover GJ; Sleph PG; Dzwonczyk S; Wang P; Fung W; Tobias D; Cushman DW
    J Pharmacol Exp Ther; 1991 Jun; 257(3):919-29. PubMed ID: 1646329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new potent inhibitor of converting enzyme: (2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid(SA446).
    Iso T; Yamauchi H; Suda H; Nakata K; Nishimura K; Iwao J
    Jpn J Pharmacol; 1981 Dec; 31(6):875-82. PubMed ID: 6174764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice.
    de Nigris F; D'Armiento FP; Somma P; Casini A; Andreini I; Sarlo F; Mansueto G; De Rosa G; Bonaduce D; Condorelli M; Napoli C
    Int J Cardiol; 2001 Dec; 81(2-3):107-15; discusssion 115-6. PubMed ID: 11744122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisinopril.
    Sun Y; Mendelsohn FA
    J Cardiovasc Pharmacol; 1991 Oct; 18(4):478-86. PubMed ID: 1724523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers.
    Marzo A; Dal Bo L; Mazzucchelli P; Monti NC; Crivelli F; Ismaili S; Giusti A; Uhr MR
    Arzneimittelforschung; 2002; 52(4):233-42. PubMed ID: 12040965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition.
    Bucci M; Vellecco V; Cantalupo A; Brancaleone V; Zhou Z; Evangelista S; Calderone V; Papapetropoulos A; Cirino G
    Cardiovasc Res; 2014 Apr; 102(1):138-47. PubMed ID: 24501330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors.
    Liu X; Engelman RM; Rousou JA; Cordis GA; Das DK
    Cardiovasc Drugs Ther; 1992 Aug; 6(4):437-43. PubMed ID: 1387799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
    Matsuno Y; Taira N; Fujitani B; Ito T; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):55-62. PubMed ID: 3513777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological properties of the angiotensin-converting enzyme inhibitor cilazapril.
    Natoff IL; Nixon JS; Francis RJ; Klevans LR; Brewster M; Budd J; Patel AT; Wenger J; Worth E
    J Cardiovasc Pharmacol; 1985; 7(3):569-80. PubMed ID: 2410692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of angiotensin converting enzyme by CV-3317, a non-sulfhydryl compound.
    Inada Y; Terashita Z; Imura Y; Tanabe M; Nishikawa K; Kikuchi S
    Jpn J Pharmacol; 1986 Sep; 42(1):99-108. PubMed ID: 3025487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril.
    Westendorp B; Schoemaker RG; van Gilst WH; van Veldhuisen DJ; Buikema H
    Eur J Pharmacol; 2005 Dec; 527(1-3):141-9. PubMed ID: 16310764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel.
    Sargent CA; Sleph PG; Dzwonczyk S; Smith MA; Normandin D; Antonaccio MJ; Grover GJ
    J Pharmacol Exp Ther; 1993 May; 265(2):609-18. PubMed ID: 8496812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs.
    Cushman DW; Wang FL; Fung WC; Harvey CM; DeForrest JM
    Am J Hypertens; 1989 Apr; 2(4):294-306. PubMed ID: 2706094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.